Evidence map›Paper›PMID 35533419›Full record

ArticleMultiple sclerosis and related disorders2022

Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis.

Sammita Satyanarayan, Neha Safi, Tali Sorets, Susan Filomena, Yinan Zhang, Sylvia Klineova, Michelle Fabian, Sam Horng, Stephanie Tankou, Aaron Miller and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis and related disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Observational
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Sammita SatyanarayanCorinne Dickinson Goldsmith Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 E 98th Street, New York, NY 10029, USA. Electronic address: Sammita.satyanarayan@mssm.edu.
Neha SafiCorinne Dickinson Goldsmith Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 E 98th Street, New York, NY 10029, USA.
Tali SoretsCorinne Dickinson Goldsmith Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 E 98th Street, New York, NY 10029, USA.
Susan FilomenaCorinne Dickinson Goldsmith Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 E 98th Street, New York, NY 10029, USA.
Yinan ZhangThe Ohio State University, Wexner Medical Center.
Sylvia KlineovaCorinne Dickinson Goldsmith Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 E 98th Street, New York, NY 10029, USA.
Michelle FabianCorinne Dickinson Goldsmith Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 E 98th Street, New York, NY 10029, USA.
Sam HorngCorinne Dickinson Goldsmith Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 E 98th Street, New York, NY 10029, USA.
Stephanie TankouCorinne Dickinson Goldsmith Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 E 98th Street, New York, NY 10029, USA.
Aaron MillerCorinne Dickinson Goldsmith Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 E 98th Street, New York, NY 10029, USA.
Stephen KriegerCorinne Dickinson Goldsmith Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 E 98th Street, New York, NY 10029, USA.
Fred LublinCorinne Dickinson Goldsmith Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 E 98th Street, New York, NY 10029, USA.
James SumowskiCorinne Dickinson Goldsmith Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 E 98th Street, New York, NY 10029, USA.
Ilana Katz SandCorinne Dickinson Goldsmith Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 E 98th Street, New York, NY 10029, USA.
Icahn School of Medicine at Mount Sinai · USThe Ohio State University Wexner Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrior studies suggest reduced humoral response to COVID-19 vaccination in immunosuppressed populations. Disease modifying therapies (DMTs) for multiple sclerosis (MS) have variable immunomodulatory effects, and limited data are available for all DMTs. We aimed to determine the impact of DMTs on antibody response to COVID-19 vaccination among MS patients.

methodsPatients with documented COVID-19 vaccination dates and anti-spike antibody results post-vaccination were identified between March-August 2021. Clinical data were retrospectively abstracted from chart review. Deidentified data were analyzed to evaluate antibody response, and multivariable logistic regression analyses were used to identify clinical and demographic predictors of antibody response. Data analysis was completed with SAS Studio, v3.8.

resultsA total of 353 individuals had documented COVID-19 vaccine and antibody test dates (58% Pfizer, 38% Moderna, and 4% Johnson & Johnson). Of these 353 patients, 72% developed antibodies, with a mean antibody test interval of 53 days (median 46) post final vaccine dose. 100% of those on no DMT (n = 34), injectables (n = 20), teriflunomide (n = 10), natalizumab (n = 71), and 97.8% of those on fumarates (n = 46/47) had a positive antibody result. One patient on cladribine (n = 1) had a negative antibody result. Of those on sphingosine-1 phosphate (S1P) modulators, 72.4% (n = 21/29) had a positive antibody result. Of those on anti-CD20 therapies, 37.6% (n = 53/141) had a positive antibody result. Multivariate modeling of the total cohort showed anti-CD20 therapy was significantly associated with lower odds of positive antibody response (OR = 0.024, 95% CI 0.01;0.05, p < 0.0001). Among S1P modulators, increased duration of therapy, and not lymphopenia, may be associated with lower odds of positive antibody response. Multivariate modeling of anti-CD20 therapies showed therapy duration < 1 year (OR 8.14, 95% CI 2.896;22.898 p < .0001) and prior COVID-19 infection (OR = 3.95, 95% CI 1.137;13.726, p = .03) were significantly associated with higher odds of a positive antibody response. In patients with recent B-cell data, mean B-cell count was higher in antibody-positive individuals compared to antibody-negative (32.9 vs. 3.9 cells, p = .0056).

conclusionMS DMTs had variable impact on antibody response with mRNA and viral vector COVID-19 vaccines. All patients on no DMT, interferons, glatiramer acetate, teriflunomide, natalizumab, and nearly all on fumarates had positive antibody responses post-vaccine. S1P modulators and anti-CD20 therapies attenuated antibody response post-vaccine. For patients on anti-CD20 therapies, shorter duration of therapy and prior COVID-19 infection predicted positive antibody response. Further studies are needed to determine clinical significance of antibody testing, development of cellular mediated immunity, and benefits of booster vaccinations.

Indexed as

COVID-19Multiple SclerosisAntibodies, ViralAntibody FormationCOVID-19 VaccinesFumaratesHumansImmunomodulationImmunosuppressive AgentsNatalizumabRetrospective StudiesAntibodies, ViralCOVID-19 VaccinesFumaratesImmunosuppressive AgentsNatalizumabAntibody responseCOVID-19Multiple sclerosisVaccine

Identifiers

PMID35533419
PMCPMC8916835
OpenAlexW4221063458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.